{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T14:54:45Z","timestamp":1775746485384,"version":"3.50.1"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Fund for Scientific Research Flanders","award":["G.0384.12N"],"award-info":[{"award-number":["G.0384.12N"]}]},{"name":"Queen Elisabeth Medical Foundation"},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["SRP40"],"award-info":[{"award-number":["SRP40"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003132","name":"Innovation by Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003132","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"FWO","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.expneurol.2016.12.009","type":"journal-article","created":{"date-parts":[[2016,12,24]],"date-time":"2016-12-24T04:49:14Z","timestamp":1482554954000},"page":"15-28","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc\u2212"],"prefix":"10.1016","volume":"290","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2527-6997","authenticated-orcid":false,"given":"Eduard","family":"Bentea","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joeri","family":"Van Liefferinge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Verbruggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katleen","family":"Martens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sho","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Deneyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Demuyser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Albertini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrien","family":"Maes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyo","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Smolders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Lewerenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"Massie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2016.12.009_bb0005","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.nbd.2009.09.002","article-title":"Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease","volume":"36","author":"Afonso-Oramas","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/187152710791292567","article-title":"Mechanisms of oxidative glutamate toxicity: the glutamate\/cystine antiporter system xc\u2212 as a neuroprotective drug target","volume":"9","author":"Albrecht","year":"2010","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0015","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1460-9568.2006.04953.x","article-title":"Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission","volume":"24","author":"Andersson","year":"2006","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089076","article-title":"Zonisamide attenuates alpha-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease","volume":"9","author":"Arawaka","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/ana.21885","article-title":"Neuroprotective effects of zonisamide target astrocyte","volume":"67","author":"Asanuma","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0030","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fnbeh.2015.00068","article-title":"Nigral proteasome inhibition in mice leads to motor and non-motor deficits and increased expression of Ser129 phosphorylated alpha-synuclein","volume":"9","author":"Bentea","year":"2015","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0035","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1097\/00001756-199709080-00002","article-title":"Neural activity mapping with inducible transcription factors","volume":"8","author":"Chaudhuri","year":"1997","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0040","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1474-4422(09)70068-7","article-title":"Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment","volume":"8","author":"Chaudhuri","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0045","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.brainres.2011.02.017","article-title":"Zonisamide-induced long-lasting recovery of dopaminergic neurons from MPTP-toxicity","volume":"1384","author":"Choudhury","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0050","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejphar.2012.05.012","article-title":"Zonisamide up-regulated the mRNAs encoding astrocytic anti-oxidative and neurotrophic factors","volume":"689","author":"Choudhury","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0055","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.expneurol.2009.11.002","article-title":"Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction","volume":"221","author":"Costa","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0060","doi-asserted-by":"crossref","first-page":"5792","DOI":"10.1523\/JNEUROSCI.5465-10.2011","article-title":"Loss of system x(c)\u2212 does not induce oxidative stress but decreases extracellular glutamate in hippocampus and influences spatial working memory and limbic seizure susceptibility","volume":"31","author":"De Bundel","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0065","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.physbeh.2015.12.018","article-title":"In-depth behavioral characterization of the corticosterone mouse model and the critical involvement of housing conditions","volume":"156","author":"Demuyser","year":"2016","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0070","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00401-012-1004-6","article-title":"Protein degradation pathways in Parkinson's disease: curse or blessing","volume":"124","author":"Ebrahimi-Fakhari","year":"2012","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0075","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4049\/jimmunol.1401108","article-title":"Inhibition of system xc\u2212 transporter attenuates autoimmune inflammatory demyelination","volume":"195","author":"Evonuk","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0080","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1523\/JNEUROSCI.23-26-08955.2003","article-title":"Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition","volume":"23","author":"Fornai","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0085","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cne.903590211","article-title":"Dopamine transporter immunoreactivity in rat brain","volume":"359","author":"Freed","year":"1995","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0090","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncb748","article-title":"Alpha-synuclein is phosphorylated in synucleinopathy lesions","volume":"4","author":"Fujiwara","year":"2002","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0095","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.neuropharm.2013.08.002","article-title":"Zonisamide regulates basal ganglia transmission via astroglial kynurenine pathway","volume":"76 Pt A","author":"Fukuyama","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0100","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jneumeth.2005.06.016","article-title":"Characterization of an improved procedure for the removal of microglia from confluent monolayers of primary astrocytes","volume":"150","author":"Hamby","year":"2006","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0105","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0166-4328(93)90104-X","article-title":"Multiple serotonin mechanisms in animal models of anxiety: environmental, emotional and cognitive factors","volume":"58","author":"Handley","year":"1993","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1000412","article-title":"Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research","volume":"8","author":"Kilkenny","year":"2010","journal-title":"PLoS Biol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0115","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1111\/j.1742-1241.2007.01365.x","article-title":"Adjunctive zonisamide for treatment refractory anxiety","volume":"61","author":"Kinrys","year":"2007","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0120","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/cdd.2011.165","article-title":"Mutation of ATF4 mediates resistance of neuronal cell lines against oxidative stress by inducing xCT expression","volume":"19","author":"Lewerenz","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0125","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1089\/ars.2011.4391","article-title":"The cystine\/glutamate antiporter system x(c)(\u2212) in health and disease: from molecular mechanisms to novel therapeutic opportunities","volume":"18","author":"Lewerenz","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0130","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1440-1681.2007.04616.x","article-title":"Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease","volume":"34","author":"Liu","year":"2007","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0135","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.expneurol.2013.03.021","article-title":"Direct intranigral administration of an ubiquitin proteasome system inhibitor in rat: behavior, positron emission tomography, immunohistochemistry","volume":"247","author":"Mackey","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/ncn3.167","article-title":"Zonisamide in the early stage of Parkinson's disease","volume":"3","author":"Maeda","year":"2015","journal-title":"Neurol. Clin. Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0145","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1097\/WNR.0b013e328312181c","article-title":"Time-dependent changes in striatal xCT protein expression in hemi-Parkinson rats","volume":"19","author":"Massie","year":"2008","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0150","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1096\/fj.10-177212","article-title":"Dopaminergic neurons of system x(c)(\u2212)-deficient mice are highly protected against 6-hydroxydopamine-induced toxicity","volume":"25","author":"Massie","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0155","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/jnc.13348","article-title":"Main path and byways: non-vesicular glutamate release by system xc\u2212 as an important modifier of glutamatergic neurotransmission","volume":"135","author":"Massie","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0160","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/00001756-200208070-00018","article-title":"Proteasome inhibition causes nigral degeneration with inclusion bodies in rats","volume":"13","author":"McNaught","year":"2002","journal-title":"Neuroreport"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0165","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1006\/exnr.2002.8050","article-title":"Altered proteasomal function in sporadic Parkinson's disease","volume":"179","author":"McNaught","year":"2003","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/brain\/awu312","article-title":"System xc\u2212 is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice","volume":"138","author":"Mesci","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0175","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/14737175.7.9.1077","article-title":"Zonisamide for the treatment of Parkinson's disease","volume":"7","author":"Miwa","year":"2007","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0180","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.parkreldis.2007.05.008","article-title":"Effects of zonisamide on experimental tremors in rats","volume":"14","author":"Miwa","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0185","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0091-3057(01)00636-0","article-title":"Chronic stress impairs rotarod performance in rats: implications for depressive state","volume":"71","author":"Mizoguchi","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0190","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2174\/1381612043453180","article-title":"Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease","volume":"10","author":"Murata","year":"2004","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0195","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0168-0102(01)00298-X","article-title":"Zonisamide has beneficial effects on Parkinson's disease patients","volume":"41","author":"Murata","year":"2001","journal-title":"Neurosci. Res."},{"issue":"Suppl. 9","key":"10.1016\/j.expneurol.2016.12.009_bb0200","first-page":"S198","article-title":"Randomized, double-blind study of zonisamide with placebo in advanced Parkinson's disease","volume":"19","author":"Murata","year":"2004","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0205","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1212\/01.wnl.0000250236.75053.16","article-title":"Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study","volume":"68","author":"Murata","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0210","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing-off in Parkinson's disease: a randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0215","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0220","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0920-1211(98)00109-0","article-title":"Biphasic effects of zonisamide on serotonergic system in rat hippocampus","volume":"34","author":"Okada","year":"1999","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0225","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1002\/mds.21013","article-title":"Ubiquitin-proteasome system and Parkinson's disease","volume":"21","author":"Olanow","year":"2006","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0230","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0235","doi-asserted-by":"crossref","first-page":"3345","DOI":"10.1523\/JNEUROSCI.5186-05.2006","article-title":"System xc\u2212 and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40","volume":"26","author":"Qin","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0240","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.tips.2008.07.005","article-title":"Animal models of anxiety: do I need multiple tests?","volume":"29","author":"Ramos","year":"2008","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0245","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa8103","article-title":"SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma","volume":"7","author":"Robert","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0250","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.13116","article-title":"Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease","author":"Sano","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0255","doi-asserted-by":"crossref","first-page":"37423","DOI":"10.1074\/jbc.M506439200","article-title":"Redox imbalance in cystine\/glutamate transporter-deficient mice","volume":"280","author":"Sato","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0260","first-page":"296875","article-title":"Patterns of cell activity in the subthalamic region associated with the neuroprotective action of near-infrared light treatment in MPTP-treated mice","volume":"2012","author":"Shaw","year":"2012","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0265","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.expneurol.2009.11.018","article-title":"The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance","volume":"221","author":"Sonsalla","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0270","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.seizure.2013.01.011","article-title":"Zonisamide for seizures in Parkinson's disease with dementia","volume":"22","author":"Tombini","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0275","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ejphar.2014.09.023","article-title":"Zonisamide suppresses endoplasmic reticulum stress-induced neuronal cell damage in vitro and in vivo","volume":"746","author":"Tsujii","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0280","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/cne.23889","article-title":"Comparative analysis of antibodies to xCT (Slc7a11): forewarned is forearmed","volume":"524","author":"Van Liefferinge","year":"2016","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2202-11-1","article-title":"Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease","volume":"11","author":"Vernon","year":"2010","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076670","article-title":"Fumaric acid esters stimulate astrocytic VEGF expression through HIF-1alpha and Nrf2","volume":"8","author":"Wiesner","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0295","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1471-4159.2010.06914.x","article-title":"Proteasome inhibition modeling nigral neuron degeneration in Parkinson's disease","volume":"115","author":"Xie","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1254\/jphs.09019FP","article-title":"Zonisamide increases dopamine turnover in the striatum of mice and common marmosets treated with MPTP","volume":"110","author":"Yabe","year":"2009","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0305","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.neuropharm.2009.05.005","article-title":"Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway","volume":"57","author":"Yamamura","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0310","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2165\/00023210-200923080-00007","article-title":"Zonisamide: in Parkinson's disease","volume":"23","author":"Yang","year":"2009","journal-title":"CNS Drugs"},{"key":"10.1016\/j.expneurol.2016.12.009_bb0315","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11011-010-9212-z","article-title":"Therapeutic effect of a novel anti-parkinsonian agent zonisamide against MPTP (1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine) neurotoxicity in mice","volume":"25","author":"Yokoyama","year":"2010","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.expneurol.2016.12.009_bb0320","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10571-012-9886-3","article-title":"Zonisamide attenuates MPP+-induced oxidative toxicity through modulation of Ca2+ signaling and caspase-3 activity in neuronal PC12 cells","volume":"33","author":"Yurekli","year":"2013","journal-title":"Cell. Mol. Neurobiol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616304186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488616304186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T03:48:44Z","timestamp":1572580124000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488616304186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":64,"alternative-id":["S0014488616304186"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.12.009","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system xc\u2212","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2016.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}